Orforglipron - Daily GLP-1 Pill

Buy Orforglipron GLP-1 Weight Loss Pills UK

What is orforglipron?

Orforglipron is a once-daily oral pill currently being developed for weight management and type 2 diabetes. It's made by Eli Lilly, the same company behind Mounjaro. 

Orforglipron belongs to a class of medications called GLP-1 receptor agonists. GLP-1 is a natural signal that already exists in your body that tells your stomach you're full, in addition to playing a vital role in regulating blood sugar levels, particularly after meals. 

Orforglipron mimics this signal, which helps to:

• Slow down digestion
• Delay stomach emptying
• Suppress your appetite

Orforglipron is a small-molecule, nonpeptide compound. This means your body can absorb and use it effectively in pill form, unlike some other GLP-1 medications that require injections.

Who is orforglipron intended for?

Orforglipron is a new oral medication being developed for weight loss and diabetes in adults.

Although it’s not yet approved and the exact eligibility criteria as a weight loss treatment isn’t final, current clinical trials suggest it may be suitable for adults with obesity, or for those who are overweight and also have a weight-related health condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or heart disease. 

Additionally, they must have tried to lose weight through diet at least once without success.

Are orforglipron weight loss pills right for you?

It's important to consider that a daily pill might not suit everyone. Some people may prefer the convenience of a weekly injection.

However, if you’ve struggled to lose weight and have obesity-related health issues, orforglipron could become an option in the future, but we’ll know the official eligibility criteria once it’s approved.

Start your weight loss consultation

How to use orforglipron

As orforglipron hasn't been approved for use in the UK yet, we’re still waiting on the specific dosing instructions to be confirmed. But since it’s an oral tablet, you can expect to take it once a day, with or without food. 

The recommended dosage might change depending on whether you’re using it for type 2 diabetes or for weight management.

If you’re considering using orforglipron for weight loss, remember that it works best when you also implement healthy lifestyle changes. 

Getting regular exercise and eating a balanced diet will help boost the benefits of your treatment. Without these changes, orforglipron might not help you reach your weight loss goals as effectively.

What to expect: results and side effects

• Over 40 weeks, patients taking orforglipron pills had an average weight loss comparable to current GLP-1 injections.
• The most common side effects reported in trials were gastrointestinal issues like nausea, vomiting, constipation and diarrhoea, similar to those experienced with GLP-1 injections. These were generally mild to moderate.

Orforglipron vs. injections: what's the difference?

GLP-1 injections like Wegovy and Mounjaro have been game-changers for many in treating obesity, but they aren't always the most convenient option. Here's why orforglipron pills could be a welcome alternative:

• More patient-friendly. Many people find pills easier and less intimidating than injections.
• Discreet. No need to worry about refrigeration or hiding injections. Orforglipron can be stored easily.
• No needles. If you have a fear of needles, this is a significant advantage.

Orforglipron vs. other weight loss pills

Rybelsus

Rybelsus is a tablet used to manage type 2 diabetes in the UK, but it isn’t approved for weight loss. Orforglipron could soon offer another pill option, this time one that’s designed to help people lose weight and support their weight loss journey.

Orlistat/Orlos

Orlistat (also known by the brand name Orlos) works differently by reducing the absorption of fat. Orforglipron might be a more appealing option for those seeking the effectiveness of GLP-1 medications in pill form.

When will orforglipron be available in the UK?

While we don't have an exact release date yet, it's expected to be available by early 2026.

Eli Lilly is aiming to send the final Phase 3 clinical trial data to the FDA by the end of 2025 for weight loss and then in early 2026 for diabetes treatment.

If the regulatory review and approval go smoothly, the medication could be on the market in the first half of 2026, though the exact timing might differ from country to country. 

To be notified as soon as orforglipron becomes available in the UK, sign up to our email alerts.

Start your weight loss consultation